LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | XL147 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 5016 | 4513 | 1.1114 | 1.1535 |
| SK-BR-3 | XL147 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4686 | 4223 | 1.1098 | 1.1643 |
| SK-BR-3 | SB590885 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4685 | 4223 | 1.1095 | 1.1638 |
| BT-20 | YM 201636 | 0.04 | uM | LJP5 | 72 | hr | 1097 | 4179 | 3769 | 1.1087 | 1.1534 |
| SK-BR-3 | Linifanib | 0.37 | uM | LJP6 | 72 | hr | 1401 | 4681 | 4223 | 1.1084 | 1.1623 |
| MCF7 | Ruxolitinib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 4523 | 4093 | 1.1052 | 1.1494 |
| MCF7 | Ruxolitinib | 1.11 | uM | LJP5 | 72 | hr | 1209 | 4523 | 4093 | 1.1052 | 1.1494 |
| BT-20 | SU11274 | 0.04 | uM | LJP5 | 72 | hr | 1097 | 4164 | 3769 | 1.1048 | 1.1479 |
| SK-BR-3 | XL147 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4661 | 4223 | 1.1039 | 1.1554 |
| BT-20 | TGX221 | 3.33 | uM | LJP5 | 72 | hr | 1097 | 4159 | 3769 | 1.1033 | 1.1457 |
| BT-20 | XL147 | 0.37 | uM | LJP5 | 72 | hr | 1097 | 4153 | 3769 | 1.1017 | 1.1435 |
| MCF7 | LDN-193189 | 0.12 | uM | LJP5 | 72 | hr | 1209 | 4506 | 4093 | 1.1010 | 1.1433 |
| MDA-MB-231 | XL147 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4962 | 4513 | 1.0993 | 1.1368 |
| Hs 578T | SB590885 | 0.12 | uM | LJP5 | 72 | hr | 658 | 4216 | 3846 | 1.0963 | 1.1162 |
| MCF7 | SU11274 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4485 | 4093 | 1.0959 | 1.1361 |
| BT-20 | PD184352 | 0.04 | uM | LJP5 | 72 | hr | 1097 | 4128 | 3769 | 1.0952 | 1.1343 |
| SK-BR-3 | Selumetinib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 4622 | 4223 | 1.0945 | 1.1415 |
| SK-BR-3 | Foretinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4620 | 4223 | 1.0941 | 1.1409 |
| BT-20 | NU7441 | 0.04 | uM | LJP5 | 72 | hr | 1097 | 4119 | 3769 | 1.0929 | 1.1310 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4613 | 4223 | 1.0924 | 1.1383 |
| BT-20 | Withaferin A | 0.04 | uM | LJP5 | 72 | hr | 1097 | 4114 | 3769 | 1.0915 | 1.1290 |
| MCF 10A | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 962 | 11572 | 10605 | 1.0912 | 1.1003 |
| BT-20 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 1097 | 4112 | 3769 | 1.0910 | 1.1284 |
| MDA-MB-231 | Withaferin A | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4923 | 4513 | 1.0907 | 1.1249 |
| BT-20 | TGX221 | 1.11 | uM | LJP5 | 72 | hr | 1097 | 4111 | 3769 | 1.0907 | 1.1279 |